CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

Group 1 - The article discusses CG Oncology and its potential positive Phase 3 outcome that could lead to a Biologics License Application (BLA) for Cretostimogene [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - Biotech Analysis Central offers a library of over 600 articles, a model portfolio of small and mid-cap stocks, and various analysis tools for healthcare investors [2] Group 2 - The article does not provide any specific financial data or performance metrics related to CG Oncology or its products [1][3][4]